In conclusion, TNFSF4 is a potential immunotherapy target due to its aberrant expression pattern in breast carcinoma, and this protein was even found to be overexpressed in carcinomas without ERBB2, ESR1, or PGR1 amplification and those without either KRAS or TP53 mutation and amplification. The gene discussed is ESR1; the disease is carcinoma.